Show simple item record

Antidepresivi i anksiolitici - novine u formulaciji tableta

dc.creatorParojčić, Jelena
dc.creatorIbrić, Svetlana
dc.creatorĐurić, Zorica
dc.date.accessioned2019-09-02T11:10:33Z
dc.date.available2019-09-02T11:10:33Z
dc.date.issued2007
dc.identifier.issn0004-1963
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/961
dc.description.abstractDevelopment of new dosage forms with uncompromised efficacy, safety and stability and improved tolerability and dosage regimen that would result in better patient compliance is an imperative in modern pharmacotherapy. Patients" adherence to dosage regimen is of great importance, especially when prolonged treatment is an issue. Therefore, novelties in formulation development for antidepressants and anxiolytics are directed towards the modified/sustained or extended release drug products and orally disintegrating tablets. There is a number and variety of new technologies employed with this respect. In the present paper, an overview of the most important technologies applied in commercially available drug products within the group of antidepressants and anxiolytics is given.en
dc.publisherSavez farmaceutskih udruženja Srbije, Beograd
dc.rightsopenAccess
dc.sourceArhiv za farmaciju
dc.titleAntidepressants and anxiolytics: Novel tablet formulationsen
dc.titleAntidepresivi i anksiolitici - novine u formulaciji tabletasr
dc.typearticle
dc.rights.licenseBY-SA
dcterms.abstractПаројчић, Јелена; Ђурић, Зорица; Ибрић, Светлана; Aнтидепресиви и анксиолитици - новине у формулацији таблета; Aнтидепресиви и анксиолитици - новине у формулацији таблета;
dc.citation.volume57
dc.citation.issue1-2
dc.citation.spage94
dc.citation.epage105
dc.citation.other57(1-2): 94-105
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs//bitstream/id/2299/959.pdf
dc.identifier.rcubconv_354
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record